癌基因C－erbB－2、抗癌基因P^（53）在乳腺癌中表达的研究──附55例乳腺癌术后随访分析

Study of C-erbB-2and P￣(53)Expression in Human Breast Cancer With 55 Clinical Follow-up Cases

应用ＳＡＢ法对５５例乳腺癌进行了Ｃ－ｅｒｂＢ－２和Ｐ^（５３）基因表达的免疫组化研究。结果：Ｃ－ｅｒｂＢ－２阳性染色主要定位于癌细胞膜上，而Ｐ５３主要定５位于癌细胞核上。Ｃ－ｅｒｂＢ－２表达阳性率为４１．８％（２３／５５），髓样癌阳性率较高（６０．０％）；其表达与组织分级呈正相关，与雌激素受体（ＥＲ）、孕激素受体（ＰＲ）状况呈负相关，表达者５年生存率显著低于表达阴性者（Ｐ＜０．０１），因而Ｃ－ｅｒｂＢ－２表达的检测可作为评估乳腺癌预后有价值的指标。Ｐ３２表达阳性率为３８．２％（２１／５５），髓样癌阳性率亦较高（６０．０％），Ｐ^（５３）表达与组织分级呈正相关，而与ＥＲ和ＰＲ的相关性无统计学意义。本研究未发现Ｃ－ｅｒＬＢ－２与Ｐ^（５３）表达的相关性，是否提示Ｐ^（５３）和Ｃ－ｅｒｂＢ－２表达产物可能在乳腺癌的发生发展中独自发挥作用尚待进一步探讨。

In this study immunohistochemical expression of C-erbB-2 and P53 oncogene proteins in 55 cases of human breast cancer was investigated.The results showed that C-erbB-2 was located on the cell membrance,and P53 was located in the cell nucleus.C-erbB-2 expression was found in 41.8%of cases(23/55)and there was a higher frequency in medullary carcinomas(60.0%).The expression of this gene showed positive correlation with histologic grade and negative correlation with estrogen and progesterone receptor status.Breast cancer patients with C-erbB-2 expression had a poorer5-year survival rate as compared with those without expression.P53expression was found in 38.2%of cases(21/55)and there was a higher frequency in medullary carcinomas(60.0%).It was associated with histologic grade and more frequent,(although no statistical significance)in negative estrogen and progesterone receptor status.There was no significant correlation between C-erbB-2 and P53 expression.